European MedTech Fundraising Highlights: Insights from Zapyrus’ Global Intelligence 

MedTech is picking up serious momentum across Europe, and the latest wave of fundraising tells a clear story: innovation isn’t slowing down anytime soon. Whether it’s AI tools changing how we diagnose disease, digital therapeutics offering new ways to manage chronic conditions, or cutting-edge tech helping preserve organs for transplant, investors are backing ideas that could genuinely change lives. These funding rounds aren’t just about capital, they’re a glimpse into where the sector is heading next. 

Led by Kevin Saem, Zapyrus, the market intelligence platform built for MedTech investors, partners, and decision-makers, has surfaced critical updates from across the continent, highlighting the startups that are gaining investor confidence and traction. These developments also demonstrate the expanding capabilities of the Zapyrus platform in identifying opportunities and trends at an international scale. 

Precision Diagnostics Push Forward 

In France, MSInsight has raised €1.6 million in seed funding to accelerate its work in precision oncology. The company is targeting one of the most complex and impactful challenges in cancer diagnostics: the identification of microsatellite instability (MSI), a key biomarker that influences treatment options, especially for immunotherapy. 

MSI is a powerful tumor-agnostic marker relevant across various cancers, including colorectal, endometrial, and gastric. While clinical guidelines now recommend MSI testing for all newly diagnosed cancers, real-world implementation remains uneven due to the complexity of interpreting genomic data. Existing tools often produce errors that can lead to incorrect treatment plans or missed therapeutic opportunities. 

MSInsight’s software solution, MSIcare, integrates next-generation sequencing (NGS) technology with advanced bioinformatics and artificial intelligence to interpret genomic data with greater precision. By significantly improving the detection of MSI markers, the platform can streamline decision-making and ensure patients receive treatments best suited to their cancer profiles. 

The funding will support final technological development, CE-IVD regulatory validation, and clinical performance studies. The company is also pushing towards minimally invasive diagnostics through blood samples and extending its capabilities to identify at-risk individuals, including those with Lynch syndrome, a genetic condition with heightened cancer susceptibility. 

AI-Enhanced Imaging for Osteoporosis Detection 

In the UK, IBEX has secured £2 million to scale its AI-driven platform designed to detect osteoporosis through standard X-rays and mammograms. This investment comes at a time when healthcare systems are actively seeking proactive solutions to reduce the burden of chronic conditions and associated costs. 

Osteoporosis, often undiagnosed until a fracture occurs, is a condition that affects millions, especially among aging populations. IBEX’s solution, IBEX BH, turns existing imaging infrastructure into a diagnostic gateway. By integrating directly with OEM systems in clinical imaging, including X-ray and mammography equipment, the company allows routine scans to also serve as early warning tools for bone health deterioration. 

In 2024, the company established key partnerships with imaging manufacturers and demonstrated its value to national health systems by showing that earlier detection reduces downstream treatment costs. With funding now in place, IBEX is preparing for a real-world rollout in clinical environments throughout 2025. 

This milestone illustrates a broader trend in MedTech: leveraging existing tools and workflows to add diagnostic value without increasing the clinical workload. It also speaks to a shift from reactive to preventive care models enabled by data and automation. 

Next-Generation Organ Preservation in Switzerland 

In Zurich, Apersys AG, a spinout from the Liver4Life project at Wyss Zurich Translational Center, has announced a new round of financing to support its work in organ preservation and transplantation. While the amount raised has not been disclosed, the strategic direction of the company and its backing signal the growing importance of advanced perfusion systems in transplant medicine. 

Apersys is developing cutting-edge technologies aimed at extending the viability of donor organs, addressing a major constraint in global transplantation: the limited time available between organ procurement and transplantation. The startup combines the expertise of surgeons, engineers, biologists, and entrepreneurs to advance a perfusion platform that keeps organs alive outside the body for longer periods, effectively buying time and increasing transplant success rates. 

The funding will accelerate research and development as the company refines its system for clinical use. As MedTech innovation continues to intersect with bioengineering and transplant science, Apersys stands out as a promising contributor in an area where demand consistently outpaces supply. 

Digital Therapeutics Gain Scale with Liva Healthcare 

Liva Healthcare, a Danish digital health company, has acquired UK-based Momenta and secured additional funding to power its expansion strategy. Though the financial terms were not made public, the acquisition signals a consolidation of expertise in digital lifestyle interventions for chronic disease management. 

Liva combines human-led coaching with digital tools to deliver therapeutic programs for conditions such as type 2 diabetes, obesity, and cardiovascular disease. With over 80,000 patients supported to date, the company is positioning itself as a major provider of evidence-based interventions for national health systems. 

Momenta, now part of Liva, has delivered in-person and digital healthy lifestyle programs to UK health authorities, particularly the NHS. Its integration into Liva’s portfolio strengthens the company’s UK presence and aligns with broader goals to expand its reach into public health systems across Europe. 

The latest funding round was led by the IBL Group through Nupo, with participation from long-standing investors such as MIG, Santos, and MajInvest. This backing will fuel further growth and R&D, as Liva continues to optimize its platform, outcomes tracking, and integration into primary care systems. 

The Role of Market Intelligence in MedTech Growth 

These fundraising milestones reflect the diversity and maturity of the European MedTech ecosystem. Whether it’s AI-enhanced diagnostics, next-generation digital therapeutics, or engineering innovations in organ preservation, startups are tackling long-standing healthcare challenges with advanced, scalable technologies. 

They also highlight the importance of precision not only in diagnostics and therapy, but in market intelligence itself. Tracking these developments, understanding where capital is flowing, and identifying which solutions are gaining regulatory and clinical traction requires access to real-time, international data. 

Zapyrus’ global intelligence platform brings clarity to a complex and fragmented market. By surfacing relevant information from multiple regions and verticals, it empowers investors, strategics, and innovators to act with confidence. As the European MedTech landscape continues to expand, access to structured, timely intelligence will become a defining advantage. 

Through ongoing monitoring of deals, partnerships, and clinical developments, Zapyrus is helping stakeholders across the value chain anticipate trends, benchmark progress, and uncover actionable insights making it not only a data provider but a strategic enabler of growth.